Phase 1 N=14 EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks
Healthy Volunteers
Primary: Quadriceps Femoris Muscle Strength — NA; NA; 9; 13 percentage of baseline measurement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 Experimental Human Infection With Neisseria Gonorrhoeae
Gonococcal Infection
Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…
Phase 1 N=57 Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
Solid Tumor · Non-small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) — 0; 0; 1; 0 Participants
Phase 1 N=127 Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Malignant Melanoma
Primary: Number of Participants With an Adverse Event (AE) — 14; 17; 16; 6 Participants
Phase 1 N=6 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · Indolent Non-Hodgkin Lymphoma · Follicular Lymphoma
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Within 28 Days of Idelalisib Exposure — 66.7; 16.7…
Phase 1 N=30 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Phase 1 N=241 Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Indolent Non-Hodgkin's Lymphoma · Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma
Primary: Duration of Exposure to IDELA — 8.1; 7.6; 4.2; 5.1 months
Phase 1 N=16 A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (BI 425809 + Memantine : BI 425809) — 9029.04; 8559.78…
Phase 1 N=16 A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers
Autism Spectrum Disorder
Primary: Maximum Plasma Concentration (Cmax) of Balovaptan — 74.83; 97.44; 79.67 ng/mL
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants
Phase 1 N=40 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
Migraine
Primary: Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab — 1841.42; 1959.96…
Phase 1 N=9 A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Acute Myeloid Leukemia
Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants
Phase 1 N=72 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Myelodysplastic Syndrome · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Lead-in Cohort (LIC) — 12; 12; 8 Participants
Phase 1 N=21 Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 1; 0 participants